Adrenal chromaffin cells (ACCs) are the neuroendocrine arm of the sympathetic nervous system and key mediators of the physiological stress response. Acetylcholine (ACh) released from preganglionic splanchnic nerves activates nicotinic acetylcholine receptors (nAChRs) on chromaffin cells causing membrane depolarization, opening voltage-gated Ca 2+ chan-
nels (VGCC), and exocytosis of catecholamines and neuropeptides. The serotonin transporter is expressed in ACCs and interacts with 5-HT 1A receptors to control secretion. In addition to blocking the serotonin transporter, some selective serotonin reuptake inhibitors (SSRIs) are also agonists at sigma-1 receptors which function as intracellular chaperone proteins and can translocate to the plasma membrane to modulate ion channels. Therefore, we investigated whether SSRIs and other sigma-1 receptor ligands can modulate stimulus-secretion coupling in ACCs. Escitalopram and fluvoxamine (100 nM to 1 lM) reversibly inhibited nAChR currents.
The sigma-1 receptor antagonists NE-100 and BD-1047 also blocked nAChR currents (% 50% block at 100 nM) as did PRE-084, a sigma-1 receptor agonist. Block of nAChR currents by fluvoxamine and NE-100 was not additive suggesting a common site of action. VGCC currents were unaffected by the drugs. Neither the increase in cytosolic [Ca 2+ ] nor the resulting catecholamine secretion evoked by direct membrane depolarization to bypass nAChRs was altered by fluvoxamine or NE-100. However, both Ca 2+ entry and catecholamine secretion evoked by the cholinergic agonist carbachol were significantly reduced by fluvoxamine or NE-100. Together, our data suggest that sigma-1 receptors do not acutely regulate catecholamine secretion. Rather, SSRIs and other sigma-1 receptor ligands inhibit secretion evoked by cholinergic stimulation because of direct block of Ca 2+ entry via nAChRs. Keywords: adrenal chromaffin cell, calcium channels, catecholamine, serotonin transporter, sigma-1 receptor. J. Neurochem. (2017) 143, 171-182. Adrenal chromaffin cells are innervated by preganglionic sympathetic neurons and comprise the neuroendocrine arm of the sympathetic nervous system. The preganglionic (splanchnic) nerve terminals release acetylcholine (ACh) which activates nicotinic acetylcholine receptors (nAChRs) on the chromaffin cells causing membrane depolarization, opening of voltage-gated Ca 2+ channels (VGCC), and exocytosis of large dense core granules. Secretion of catecholamines and neuropeptides into the bloodstream then mediates widespread physiological responses to stress (e.g., the fight or flight response). This stimulus-secretion coupling is precisely regulated by neuronal, autocrine/paracrine, and endocrine signals acting via G protein coupled receptors including purinergic, opioid, prostanoid, histaminergic and various peptidergic receptors (Currie 2010; Jewell and Currie 2013) . Voltage-gated Ca 2+ channels are one well-characterized target for this G protein coupled receptor-mediated regulation of stimulus-secretion coupling, although additional targets might include the exocytotic machinery (Betke et al. 2012; Zamponi and Currie 2013) . Another potential target of endogenous modulators or exogenous drugs are the nAChRs, which in chromaffin cells are predominantly the 'ganglionic' isoform (a3b4* containing channels) although other subunits are also expressed in a species-dependent manner (Sala et al. 2008) . Some neuropeptides (e.g., Substance P, calcitonin gene-related peptide, or catestatin) and steroids (e.g., progesterone) can directly bind to and modulate nAChRs (Clapham and Neher 1984; Simmons et al. 1990; Mahata et al. 1997; Di Angelantonio et al. 2003; Armstrong and Stuenkel 2005; Sala et al. 2008) . It has also been reported that sigma receptors modulate chromaffin cell nAChRs (Paul et al. 1993) .
Sigma-1 receptors are chaperone proteins mainly located in the endoplasmic reticulum near the interface with mitochondria where they can help control intracellular calcium signaling (Maurice and Su 2009; Kourrich et al. 2012; Hayashi 2015; Su et al. 2016) . Upon agonist binding, the receptor can also translocate to the plasma membrane and modulate the function of various protein partners including voltage-gated and ligand-gated ion channels (Aydar et al. 2002; Zhang and Cuevas 2002; Johannessen et al. 2009; Pabba et al. 2014; Pan et al. 2014) . The endogenous ligands are still unclear (Chu and Ruoho 2016) , but the sigma-1 receptors have been implicated in a variety of pathological conditions including depression, addiction, and pain (Kourrich et al. 2012; Hashimoto 2013; Hayashi 2015; Su et al. 2016) . Related to this, a diverse array of drugs intended for other primary targets also bind to sigma-1 receptors; for example, the primary target of selective serotonin reuptake inhibitors (SSRIs) is the serotonin transporter (SERT: SLC6A4), but some of these widely prescribed antidepressants can also bind to sigma-1 receptors with moderate-tohigh affinity (e.g., fluvoxamine % 17-36 nM) (Narita et al. 1996; Sanchez and Meier 1997; Sanchez et al. 2003; Ishima et al. 2014) .
The serotonin transporter is expressed in adrenal chromaffin cells (Schroeter et al. 1997; Brindley et al. 2017 ) and we recently reported that block of SERT by escitalopram facilitated the ability of serotonin to inhibit secretion via 5-HT 1A receptors (Brindley et al. 2016) . We were interested in whether SSRIs could also act via other targets to control catecholamine secretion. For example, SSRIs have been reported to directly block nAChRs in other cell types, albeit at relatively high concentrations (1-10 lM) above the expected therapeutic range (Garcia-Colunga et al. 1997; DeVane 1999; Fryer and Lukas 1999; Hennings et al. 1999; Arias et al. 2010b; Weber et al. 2013) . Escitalopram has moderate affinity (% 300 nM) and fluvoxamine has high affinity (17-36 nM) at the sigma-1 receptor (Narita et al. 1996; Ishima et al. 2014) . Therefore, we set out to determine if these SSRIs can modulate nAChR/stimulus-secretion coupling by virtue of agonist actions at sigma-1 receptors in adrenal chromaffin cells. Our data suggest that sigma-1 receptors are not directly involved in the acute regulation of adrenal catecholamine release. Rather, sigma-1 receptor ligands, including the SSRI fluvoxamine, block calcium entry through nAChRs and thus catecholamine secretion.
Materials and methods
Ethical approval/animals All procedures using mice were subject to prior approval by the Institutional Animal Care and Use Committee of Vanderbilt University Medical Center and complied with appropriate laws and guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) (RRID: IMSR_JAX:000664) were group housed on a 12:12 hour light/dark cycle with food and water available ad libitum. Mice were euthanized using carbon dioxide inhalation followed by cervical dislocation.
Cell culture -bovine adrenal chromaffin cells Bovine adrenal glands (from male animals) were obtained from a local slaughterhouse and chromaffin cells were isolated by digestion of the adrenal medullae with collagenase followed by density gradient centrifugation (Todd et al. 2012) . For patch clamp experiments, cells were plated onto collagen-coated coverslips in 35 mm tissue culture dishes at a density of~0.1 to 0.15 9 10 6 cell/mL. For catecholamine secretion experiments, the cells were plated in 24-well tissue culture plates at a density of~0.3 9 10 6 cells per well. Cells were maintained in a humidified incubator at 37°C and 5% CO 2 in culture medium that consisted of Dulbecco's modified Eagle medium/F12 (1 : 1) supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin/ streptomycin (100 unit/mL per 100 lg/mL), 10 lM cytosine arabinoside (Sigma-Aldrich; St Louis, MO, USA), and 10 lM 5-fluorodeoxyuridine. All tissue culture reagents were from Life Technologies (Grand Island, NY, USA) unless noted otherwise. Fibroblast proliferation was suppressed with cytosine arabinoside leaving relatively pure chromaffin cell cultures. The culture medium was replaced the day after isolation and experiments were performed 2-5 days following cell isolation.
Cell culture -mouse adrenal chromaffin cells As previously described (Brindley et al. 2016) , adrenal glands were harvested from euthanized male mice (7-16 weeks old), placed on ice in Locke's solution (154 mM NaCl, 5.6 mM KCl, 2.1 mM Na 2 HPO 4 .7H 2 O, 0.8 mM Na 2 HPO 4 , 10 mM glucose, and 10 mM HEPES, pH 7.4) and trimmed of fat. The adrenal cortex was dissected from the glands, and the medullae were incubated for 20 min at 37°C in NeuroPapain solution (1.5 mg/mL; Genlantis, San Diego, CA, USA) supplemented with bovine serum albumin (0.5 mg/mL), CaCl 2 (1 mM), L-cysteine (0.5 mM), and EDTA (0.5 mM). This was followed by a 5-min incubation in ovomucoid trypsin inhibitor (2.5 mg/mL; Worthington Biochemical Corporation, Lakewood, NJ, USA) with bovine serum albumin (0.5 mg/mL) and three washes in Locke's solution. The medullae were transferred to growth medium consisting of Dulbecco's modified Eagle's medium/F12 with Glutamax (Life Technologies), fetal bovine serum (10%; GE Healthcare Life Sciences, Logan, UT, USA), and penicillin/streptomycin (100 units/mL per 100 lg/mL; Mediatech, Inc., Manassas, VA, USA) and triturated with a series of firepolished glass pipettes with decreasing tip diameters. The resulting chromaffin cell suspension was plated onto glass coverslips thinly coated with growth-factor reduced Matrigel (BD Biosciences, Bedford, MA, USA) in 35 mm dishes. Cells were allowed to adhere to the coverslips for approximately 1 h at 37°C in a humidified, 5% CO 2 atmosphere before addition of 2 mL of growth medium to the dish. Culture medium was replaced the following day and cells were recorded from 2 to 5 days after isolation.
Patch clamp electrophysiology
Patch pipettes were prepared from borosilicate glass capillary tubes (World Precision Instruments, Sarasota, FL, USA) using a Sutter P-97 pipette puller (Sutter Instrument, Novato, CA, USA). Pipettes were coated close to the tip with dental wax (Electron Microscopy Sciences, Hatfield, PA, USA) and fire-polished to a final resistance of~2 MΩ using a Narishige MF-830 microforge (Narishige, Amityville, NY, USA). Coverslips with cells attached were transferred to a recording bath (volume~300 lL) that was continually perfused with fresh solution at a flow rate of~3-4 mL/min from gravity-fed reservoirs. All experiments were performed at room temperature (~23-25°C acute application of drugs, I Ca was evoked by a 20-ms step to 0 mV once every 20 s. I Ca data were subjected to offline, linear capacitance, and leak subtraction using P/N protocols (P/-4 or P/-8) applied following the test pulses. I Ca evoked by trains of brief step depolarizations was not subject to P/N protocols. For nicotinic currents, cells were voltage-clamped at À80 mV and currents evoked by fast bath application of carbachol or 1,1-Dimethyl-4-phenylpiperazinium (DMPP). The 'peak' nAChR current was determined as the mean of a 3-s period around the maximal inward current (~10 s after solution exchange). Membrane potential was recorded in the fast current clamp mode of the EPC10 amplifier using Patchmaster software. To determine membrane resistance, the potential evoked by 100 ms current steps (À10 pA) was recorded.
Resting potential was determined as the average potential recorded over a 1-s period prior to drug application; the plateau response to cholinergic stimulation was determined by taking the average over a 1-s period commencing 15 s after drug application. Raw data were analyzed with FitMaster software (HEKA Instruments Inc.) or ClampFit (Molecular Devices). Data were then collated and subjected to additional analyses, graphing, and statistical comparison using OriginPro7 software (OriginLab Corporation, Northampton, MA, USA) or Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
Catecholamine secretion experiments
Cells in 24-well plates were washed with extracellular solution and equilibrated in this solution for 20 min at~37°C. This solution was then discarded and replaced with fresh solution with either vehicle (H 2 O) or drugs (fluvoxamine or NE-100) added to the indicated concentration (100 nM to 1 lM). Following the drug pre-incubation period, the solution was removed and replaced with extracellular solution containing 30 mM KCl or 100 lM carbachol to stimulate secretion. For drug-treated cells, the appropriate drug was also included in the stimulation solution. After a 10-min stimulation period at~37°C, the cells were placed on ice, and the solution was quickly removed and added to an equal volume of ice-cold 0.4 M perchloric acid. The cells were lyzed by addition of perchloric acid and scraping to extract the non-secreted catecholamines. The catecholamine content of the samples was determined by a specific high performance liquid chromatography (HPLC) assay utilizing an Antec Decade electrochemical detector in the Vanderbilt Brain Institute Neurochemistry Core as described previously (Todd et al. 2012) . Staff members performing the HPLC analyses were blinded to the treatment groups. The amount of catecholamine secreted during the 10-min stimulation period was expressed as a percentage of the total catecholamine content for that well of cells to account for any potential differences in cell plating density.
Carbon fiber amperometry Amperometric data were collected using commercially available carbon fiber electrodes (5 lm diameter) (CFE-2; ALA Scientific Instruments, Farmingdale, NY, USA) as previously described (Brindley et al. 2016) . A potential of +700 mV was applied to the electrode and data were recorded using a VA-10X amplifier (NPI Electronic; GmbH, Tamm, Germany), a 16-bit BNC-2090 analog to digital converter (National Instruments, Austin, TX, USA), and WinEDR software written by Dr. John Dempster (Strathclyde University, Glasgow, Scotland). Amperometric currents were filtered at 2 kHz and continuously sampled at 10 kHz. Each carbon fiber electrode was used multiple times with the fiber carefully cut back between every cell to reveal a fresh oxidation surface and to minimize electrode fouling. Chromaffin cells were placed into the recording bath (volumẽ 300 lL) and continually perfused with extracellular solution from gravity-fed reservoirs at a rate of~3 mL/min for 5 min prior to and throughout the recording. Secretion was stimulated either by bath application of carbachol or by trains of brief step depolarizations in voltage-clamped cells. The experimental/drug application paradigm for each set of data is explained in the Results section and/or figure legends. Recordings were alternated between control cells and cells with the various drug treatments. This was done to randomize the influence of any variability because of cell preparations, recording solutions, electrode characteristics, etc. Amperometric spikes were detected and analyzed using the Quanta Analysis macros written by Dr. Eugene Mosharov (Mosharov and Sulzer 2005) in IgorPro software (Wavemetrics Inc., Oswego, OR, USA) as previously described (Brindley et al. 2016) . To assess the number of vesicular fusion events, all spikes ≥ 3 pA with rise time (25-75%) between 0.5 and 100 ms were counted. This included spikes that overlapped by ≤ 50%. All detected spikes were confirmed by visual inspection. After detection of spike number and parameters using the IgorPro macros, the data were collated and analyzed using OriginPro 7 (OriginLab Corporation) and Prism 5 software (GraphPad Software Inc.).
Fluorescent imaging of cytosolic [Ca

2+
] i Free cytosolic [Ca 2+ ] was measured in cells loaded with the fluorescent Ca 2+ indicator Fura-4F-AM (Setareh Biotech, LLC, Eugene, OR, USA) using an InCyt IM2 fluorescence imaging system (Intracellular Imaging Inc, Cincinnati, OH, USA). Cells were washed twice with HEPES-buffered Hank's balanced salt solution and incubated with 5 lM Fura-4F-AM at 37°C for~45 min, protected from light. Cells were then washed twice in Fura free solution and used after sitting for at least 25 min at room temperature, protected from light. Coverslips were transferred to a recording chamber mounted on a Nikon TE2000 fluorescence microscope (Nikon Instruments Inc., Melville, NY, USA). The recording bath was continually perfused with extracellular solution from gravity-fed reservoirs at a flow rate of~3-4 mL/min. Typically, between 3 and 10 individual cells were selected in the field of view for analysis. Cells were excited at wavelengths of 340 and 380 nm and emission detected at 510 nM with a PixelFly digital camera. The ratio of fluorescence emission at the two excitation wavelengths (340/380 nm) was measured every 1 s. Data were transferred to OriginPro2016 for further graphing and analysis. Tetrodotoxin (R&D systems) was prepared as a 1 mM aqueous stock and aliquots frozen until use (final concentration when diluted into extracellular solution was~0.5-0.75 lM). Stocks of carbachol (100 mM), DMPP (50 mM), escitalopram (20 mM), fluvoxamine (10 mM), NE-100 (25 mM), BD-1047 (10 mM), and PRE-084 (50 mM) (all from Sigma-Aldrich, St Louis, MO) were prepared in sterile water and frozen or stored at 4°C (carbachol) until use. On the day of use, an aliquot was diluted (> 1000 fold dilution) into extracellular solution to the final working concentrations (100 lM for carbachol; 30 nM to 1 lM for fluvoxamine and NE-100).
Statistical analysis
Staff members were not blinded to the drug application paradigm except for those performing the sample extraction and raw HPLC analyses in the Vanderbilt Neurochemistry core facility. Graphing and statistical analyses were performed using OriginPro7, OriginPro 2016, and/or GraphPad Prism 5 software. The specific tests that were used are noted in the results section and/or figure legends. When comparing two datasets, Student's t-test was used. When comparing multiple (> 2) groups, one-way ANOVA (repeated measures when appropriate) or two-way repeated measures ANOVA was used with multiple pairwise comparisons performed using Dunnett's or Bonferroni's post hoc tests (as noted for each dataset). Differences were considered statistically significant if p < 0.05.
Results
Reversible, concentration-dependent block of nAChR currents by escitalopram and fluvoxamine The primary target for selective SSRIs is the serotonin transporter (SERT), but some of these widely used antidepressants can also interact with other targets including sigma-1 receptors and nicotinic ACh receptors (nAChRs). Fluoxetine, paroxetine, sertraline, and citalopram can all block nAChRs, albeit at relatively high concentrations compared to those needed to block SERT (Garcia-Colunga et al. 1997; Fryer and Lukas 1999; Hennings et al. 1999; Arias et al. 2010b; Weber et al. 2013) . We tested the ability of escitalopram (the 'active' S-enantiomer of citalopram) and fluvoxamine to block nAChRs in bovine sympathoadrenal chromaffin cells using whole cell patch clamp recording. Chromaffin cells express a variety of nicotinic receptor subunits but the relatively non-desensitizing 'ganglionic' (a3b4*) channels predominate (Sala et al. 2008) . In cells voltage-clamped at À80 mV, 30 s applications of carbachol (100 lM) evoked robust inward currents, consistent with previous reports (Dzhura et al. 2006; Jewell et al. 2011) (Fig. 1a) . The maximal inward current amplitude was determined by taking an average over a 3-s window at the peak of the response. In control cells, repeated carbachol stimulation at 5-min intervals evoked reproducible responses with no significant change in current amplitude (Fig. 1a and d) . This enabled an experimental paradigm in which each cell was stimulated multiple times: in the absence, presence, and after washout of a test compound (Fig. 1b and c) . Both escitalopram and fluvoxamine produced reversible, concentration-dependent block of nAChR currents at concentrations ≤ 1 lM (Fig. 1b-g ).
Sigma-1 receptor antagonists and agonists blocked nAChR currents and occluded the block by fluvoxamine In addition to blocking the serotonin transporter, fluvoxamine is a high affinity agonist (% 15-40 nM) at sigma-1 receptors (Narita et al. 1996; Sanchez and Meier 1997; Sanchez et al. 2003; Ishima et al. 2014) . Sigma-1 receptor agonists have been reported to inhibit nicotinestimulated Ca 2+ entry and catecholamine secretion from bovine adrenal chromaffin cells (Paul et al. 1993) . Therefore, we first exposed cells to NE-100 (100 nM), a selective sigma-1 receptor antagonist, to determine if this prevented the inhibition of nAChRs produced by fluvoxamine (Fig. 2) . However, NE-100 itself significantly reduced the nAChR current to 44 AE 5% of control amplitude (n = 6). When fluvoxamine (100 nM) was applied in the continued presence of NE-100, the current amplitude remained unchanged relative to NE-100 alone (47 AE 3% of control amplitude) (Fig. 2a) and following washout of both drugs, the current amplitude recovered to 90 AE 8% of control. In other experiments, we reversed the order of drug application and found the same nonadditive inhibition (Fig. 2b) . Cells in (b) and (c) were exposed to escitalopram (100 nM and 1 lM) or fluvoxamine (100 nM and 1 lM) for 2 min before and during the second and third stimulations, followed by washout of the drug for 2-min prior to the fourth stimulation. (d) Peak current amplitude (mean AE SEM) for each of the four carbachol stimulations from control cells (n = 12) like that shown in (a). There was no significant change in current amplitude evoked by repeated carbachol stimulation (F = 1.51, p = 0.23, one-way repeated measures ANOVA; ns = not significant compared to the first stimulation ('before') using Dunnett's multiple comparison test). (e) Peak current amplitude (mean AE SEM) from cells exposed to escitalopram as in (b) (F = 13.2, p = 0.0004, n = 5, one-way repeated measures ANOVA; ns = not significant, ***p < 0.001 compared to the first stimulation ('before') using Dunnett's multiple comparison test). (f) Peak current amplitude (mean AE SEM) from cells exposed to fluvoxamine as in (c) (F = 33.2, p < 0.0001, n = 6, one-way repeated measures ANOVA; ns = not significant, **p < 0.01, ***p < 0.001 compared to the first stimulation ('before') using Dunnett's multiple comparison test). (g) Percent change in current amplitude produced by the indicated concentrations of escitalopram or fluvoxamine. Current amplitude in the presence of drug is shown as a percentage of control amplitude before drug application in the same cell (**p < 0.01, ***p < 0.001 calculated by within cell comparison to control amplitude using one-way repeated measures ANOVA with Dunnett's post-test).
Further experiments showed that NE-100 produced a robust, reversible, concentration-dependent block of the nAChR currents (Fig. 3a-c) . Another sigma-1 receptor antagonist, BD1047, produced a similar concentrationdependent block of nAChR currents (Fig. 3d) and PRE-084, a sigma-1 receptor agonist, also blocked the nAChR current, albeit at concentrations > 1 lM (Fig. 3e) . Thus, all the sigma-1 ligands tested produced a rapid, readily reversible block of nAChR currents in adrenal chromaffin cells. However, this block did not correlate with reported actions at sigma-1 receptors, as both agonists and antagonists had the same inhibitory effect.
Fluvoxamine robustly blocked nAChR currents in mouse chromaffin cells but only modestly reduced Ca 2+ entry evoked by cholinergic agonists We recorded nAChR currents in chromaffin cells isolated from mouse adrenal glands and confirmed that fluvoxamine produced a similar block to that seen in bovine cells (Fig. 4a  and b) . For these experiments, we used amphotericin Bperforated whole cell recording which is less disruptive to the intracellular calcium buffers and diffusible signaling pathways. As shown in Fig. 4(a) , 1 lM fluvoxamine reversibly blocked the nAChR current evoked by 30 lM DMPP, a selective nicotinic receptor agonist. In other cells, we used current clamp recording to determine the effect of fluvoxamine on the membrane depolarization evoked by DMPP. The input resistance determined using brief hyperpolarizing current steps was 3.28 AE 0.38 GΩ (n = 7) and was not altered by 1 lM fluvoxamine (3.13 AE 0.35 GΩ, n = 7; p = 0.32, paired t-test). In control conditions, DMPP (30 lM) produced a sustained membrane depolarization that reversed upon washout (Fig. 4c) . The cells typically fired several action potentials at the onset of membrane depolarization and in some cases during washout of the DMPP (Fig. 4c) . Fluvoxamine (1 lM) had no effect on the membrane potential under basal conditions (before application of DMPP), or on the depolarization produced by DMPP ( Fig. 4c and d) . The number of action potentials evoked by DMPP application was not altered by fluvoxamine (control Fig. 2 Block of nAChR currents by co-application of fluvoxamine and NE-100. Bovine adrenal chromaffin cells were stimulated by four applications of carbachol as in Fig. 1 . NE-100 (100 nM) and/or fluvoxamine (100 nM) were present before and during the second and third stimulations as indicated. (a) NE-100 (100 nM) was applied first and significantly blocked the current. Fluvoxamine (100 nM) had no additional effect (F = 13.4, p = 0.0002, one-way repeated measure ANOVA; ns = not significant and **p < 0.01 compared to control (before); nsd not significantly different for indicated pairwise comparison using Bonferroni multiple comparison post-test). (b) Fluvoxamine (100 nM) was applied first and significantly blocked the current. There was no additional effect when NE-100 (100 nM) was added (F = 32.5, p < 0.0001, one-way repeated measure ANOVA; ns = not significant and ***p < 0.001 compared to control (before); nsd not significantly different for indicated pairwise comparison using Bonferroni multiple comparison post-test). Fig. 3 Reversible, concentration-dependent block of nAChR currents by the sigma-receptor ligands NE-100, BD1047, and PRE-084. (a) Whole cell patch clamp recordings of nAChR currents from a bovine adrenal chromaffin cell (as in Fig. 1 ). The nAChR current was blocked in a concentration-dependent manner by NE-100 and fully recovered after washout. (b) Peak current amplitude (mean AE SEM) from NE-100 treated cells (n = 6) like that shown in (a) (F = 11.01, p = 0.0004, oneway repeated measures ANOVA; *p < 0.05, **p < 0.001, ns = not significant compared to the first stimulation ('before') using Dunnett's multiple comparison test). (c-e) Change in current amplitude produced by the indicated concentrations of NE-100 (c), BD-1047 (d), or PRE-084 (e). Current amplitude in the presence of drug is shown as a percentage of control amplitude before drug application in the same cell. ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001 calculated by within cell comparison to control amplitude using one-way ANOVA with Dunnett's post-test. 7.9 AE 1.2; fluvoxamine 7.1 AE 1.4, n = 7, p = 0.31 paired ttest).
We also used fluorescent imaging of FURA-4F-loaded mouse chromaffin cells to monitor cytosolic [Ca 2+ ] (Fig. 4e  and f) . Fluvoxamine (1 lM) had no effect on baseline fluorescence. In control cells, a 5-min application of DMPP (30 lM) or carbachol (300 lM) produced similar increases in [Ca 2+ ] (Fig. 4e) . In the presence of 1 lM fluvoxamine, the peak response was modestly reduced in cells stimulated with either DMPP (21 AE 3%, n = 43, p < 0.0001) or carbachol (17 AE 3%, n = 61, p < 0.0001) (Fig. 4f) . In contrast, fluvoxamine had no effect on the [Ca 2+ ] elevation produced by direct membrane depolarization with 30 mM KCl (increase of 2 AE 3%, n = 66, p = 0.56) (Fig. 4f) . To summarize, fluvoxamine robustly inhibited nAChR currents but this had little effect on membrane depolarization. Fluvoxamine had no effect on KCl-evoked Ca 2+ entry, suggesting that the modest (~20%) reduction in cholinergic-evoked Ca 2+ elevation was because of block of Ca 2+ entry directly through nicotinic channels.
Voltage-gated Ca
2+ channel currents (I Ca ) were not blocked by fluvoxamine, escitalopram, or NE-100 Voltage-gated Ca 2+ channels (VGCCs) play a pivotal role in stimulus-secretion coupling downstream from nAChRs and have been reported to be modulated by sigma-1 receptors in sympathetic and sensory neurons (Zhang and Cuevas 2002; Pan et al. 2014) . Our Ca 2+ imaging data in cells stimulated with KCl suggested that fluvoxamine had no effect on VGCCs (Fig. 4f) . To confirm this, we recorded whole cell voltage-gated Ca 2+ channel currents (I Ca ) in bovine chromaffin cells evoked by short (20 ms) step depolarizations from À80 to 0 mV every 20 s (Fig. 5a ). Acute application of escitalopram (1 lM), fluvoxamine (1 lM), or NE-100 (3 lM) had no effect on I Ca (Fig. 5a and b) . In other experiments, we found no effect on I Ca even with longer fluvoxamine treatment. In these experiments, fluvoxamine (1 lM) was added to the cell culture medium for~15-20 min prior to transferring the cells to the recording bath with extracellular recording solution also containing 1 lM fluvoxamine throughout the experiment. Control cells were treated in the same manner except that vehicle (H 2 O) was added to the solutions at the same dilution (1 in 10 000). Cells were voltage-clamped at À80 mV and stimulated with a series of step depolarizations to generate a current-voltagerelationship (Fig. 5c ). Peak I Ca density was not significantly different in fluvoxamine-treated cells compared to controls (p = 0.085, unpaired t-test). We performed similar experiments in mouse chromaffin cells using amphotericin Bperforated whole cell recording. Fluvoxamine (1 lM) had no Fluvoxamine significantly reduced the response to DMPP and carbachol but not KCl (***p < 0.0001; ns denotes p = 0.56 for fluvoxamine compared to control cells using Student's t-test).
effect on peak I Ca density which was 55.7 AE 4.7 pA/pF (n = 5) in control cells and 55.5 AE 4.9 pA/pF (n = 8) in cells treated with fluvoxamine (p = 0.97, t-test). To summarize, concentrations of escitalopram, fluvoxamine, or NE-100 that produced robust (> 70-90%) block of nAChR currents had no effect on I Ca .
Fluvoxamine and NE-100 inhibited catecholamine secretion evoked by carbachol but not when cells were directly depolarized to bypass nAChRs First, we used HPLC to measure secretion from bovine chromaffin cells plated in 24-well culture dishes (~300 000 cells per well). Carbachol (100 lM) was added to the cells for 10 min and the media collected to determine the amount of secreted catecholamines using HPLC. Alternatively, cells were stimulated with 30 mM KCl which directly depolarizes the plasma membrane to open voltage-gated Ca 2+ channels and trigger secretion, bypassing the nAChRs. Fluvoxamine (100 nM and 1 lM) significantly inhibited carbachol-evoked catecholamine secretion, whereas KCl-evoked secretion was not significantly different from control cells (Fig. 6a) . Similarly, NE-100 (1 lM) significantly reduced carbacholevoked secretion but not KCl-evoked secretion (Fig. 6b) .
As a more sensitive measure of secretion, we used carbon fiber amperometry to record catecholamine exocytosis from individual mouse chromaffin cells (Fig. 7) . Each 'spike' on the amperometry current recording is because of oxidation of the catecholamine released by exocytosis of a single secretory vesicle. Cells were stimulated by a 5-min bath perfusion with carbachol (300 lM) and recordings were alternated between control cells and cells exposed to either fluvoxamine (1 lM) or NE-100 (1 lM) for 5-min prior to and during carbachol stimulation. Most secretion occurred during the first 2-3 min of stimulation (Fig. 7 ). Fluvoxamine and NE-100 both produced a significant, time-dependent reduction in secretion (Fig. 7b) . To bypass cholinergic stimulation, we used amphotericin B-perforated whole cell patch clamp recording in combination with amperometry to monitor secretion (Fig. 8) . Voltage-clamped cells were stimulated by 10 Hz trains of brief step depolarizations (5 ms steps from À80 to +10 mV), first in the absence and then in the presence of 1 lM fluvoxamine. Other cells served as time-matched controls (i.e., no fluvoxamine was present during the second train). Fluvoxamine (1 lM) had no effect on the number of amperometric spikes evoked by the stimulus train (i.e., number of vesicles released) (Fig. 8b) . The charge (integral) of each spike is directly proportional to the number of catecholamine molecules released by single vesicular fusion events and was not significantly different in the absence or presence of fluvoxamine (0.22 AE 0.03 pC under control conditions and 0.21 AE 0.02 pC with fluvoxamine present; n = 13, p = 0.61). Fluvoxamine also had no effect on I Ca evoked by the stimulus trains (Fig. 8c) . To summarize, fluvoxamine and NE-100 inhibited Ca 2+ entry and secretion when cells were stimulated with the cholinergic agonist carbachol. However, when nAChRs were bypassed with either KCl or in voltage-clamp recordings, the drugs had no effect on Ca 2+ entry or secretion. The simplest interpretation of our data is that the drugs inhibited secretion because of direct block of Ca 2+ entry via nAChRs.
Discussion
The SERT plays a key role in controlling serotonergic signaling in the CNS and is the primary target for antidepressant SSRIs. SERT is prominently expressed in adrenal chromaffin cells (Schroeter et al. 1997; Brindley et al. 2017) and we recently reported that block of SERT by escitalopram augmented the ability of 5-HT to inhibit catecholamine secretion via 5-HT 1A receptors (Brindley et al. 2016) . SSRIs can also interact with other targets; fluoxetine, paroxetine, sertraline, and citalopram have all been reported to block nAChRs, albeit at relatively high concentrations (% 1-10 lM) (Garcia-Colunga et al. 1997; Fryer and Lukas 1999; Hennings et al. 1999; Arias et al. 2010b; Weber et al. 2013) . Some SSRIs, in particular fluvoxamine, are also agonists at sigma-1 receptors with reported binding affinities close to or within the clinically relevant range (Narita et al. 1996; Sanchez and Meier 1997; Sanchez et al. 2003; Ishima et al. 2014) . Moreover, sigma receptors have been reported to modulate nAChRs and catecholamine secretion in chromaffin cells (Paul et al. 1993) . Therefore, we set out to determine if SSRIs might act via sigma-1 receptors to control nAChRs and/or catecholamine secretion in adrenal chromaffin cells.
SSRIs and sigma-1 receptor ligands directly blocked nAChRs but not voltage-gated Ca 2+ channels
Our data show that all the drugs tested robustly inhibited nAChR currents in chromaffin cells including those that are agonists (fluvoxamine, escitalopram, PRE-084) and those that are antagonists at sigma-1 receptors (NE-100, BD-1047) (Figs 1-4) . The onset and washout of the nAChR inhibition was rapid, suggesting that it was not because of trafficking of the channels or drug action at intracellular sites which would be expected to reverse more slowly. Sigma-1 receptors have also been reported to modulate I Ca in sympathetic and sensory neurons (Zhang and Cuevas 2002; Pan et al. 2014) . However, we found no effect of fluvoxamine, escitalopram, or NE-100 on I Ca in chromaffin cells, even at high concentrations (1-3 lM) that produced > 70-90% block of nAChRs (Fig. 5) . Together, our data suggest the drug effects are because of direct block of nAChRs and are not mediated through sigma-1 receptors. The SSRIs fluoxetine, paroxetine, sertraline, and citalopram directly block nAChRs in other cell types (Garcia-Colunga et al. 1997; Fryer and Lukas 1999; Arias et al. 2010b; Weber et al. 2013) . Our data show that escitalopram and fluvoxamine share this property, and also demonstrate block of nAChRs by selective sigma-1 ligands.
To the best of our knowledge, this is the first demonstration that these sigma-1 receptor ligands directly block nAChR currents, although inhibition of nicotine-evoked calcium entry or potassium efflux by sigma-1 ligands in PC12 cells reportedly did not involve sigma-1 receptors (Yamamoto et al. 1992; Sagi et al. 1996) . Although we did not investigate the binding site for the drugs on nAChRs, we did find that fluvoxamine occluded block by NE-100 and vice-versa. This suggests that both drugs interact with the same or nearby site(s) on the receptor complex. It seems reasonable to speculate that this might be the same site(s) within the pore region of the receptor reported for other SSRIs (Arias et al. 2010a ).
The concentrations of fluoxetine, paroxetine, sertraline, and citalopram reported to directly block nAChRs are relatively high (IC 50 % 1-10 lM) compared to plasma concentrations in patients estimated to be in the tens to low hundreds of nM (Garcia-Colunga et al. 1997; Fryer and Lukas 1999; Arias et al. 2010b; Weber et al. 2013) . Therefore, it has been suggested that there would be little block of a4b2* receptors in the CNS at clinically relevant concentrations of citalopram (Weber et al. 2013) . Our data show that escitalopram and fluvoxamine were effective at submicromolar concentrations (fluvoxamine inhibited nAChR currents by % 50% block at 100 nM) (Fig. 1) . The reason for this increased sensitivity of chromaffin cell nAChRs to SSRIs will require further investigation, but it raises the possibility that there could be some block at the high-end of clinically relevant concentrations (100-300 nM). Chromaffin cells predominantly express a3b4* receptors, although several other subunits might also contribute and potentially shift the sensitivity to block by SSRIs (Sala et al. 2008) . Even though 1 lM fluvoxamine robustly blocked the nAChR currents (by~75%), it had no effect on the membrane depolarization produced by the nicotinic agonist DMPP (Fig. 4c and d) . In part, this might reflect the high input resistance of chromaffin cells which leads to substantial changes in membrane potential even with small changes in current flow. Moreover, it has been suggested that there is a functional reserve of 'spare' nAChRs on adrenal chromaffin cells (Wenger et al. 1997) . This would mean that a large fraction of the receptors need to be blocked before membrane depolarization is altered, thereby mitigating the impact of SSRIs or other drugs that block nAChRs.
Catecholamine secretion was inhibited due to block of nAChRs Fluvoxamine (an SSRI/sigma-1 agonist) and NE-100 (a sigma-1 antagonist) both significantly reduced catecholamine secretion evoked by the cholinergic agonist carbachol (Fig. 6 and  7) . However, secretion evoked by 30 mM KCl which directly depolarizes the plasma membrane (bypassing nAChRs) was not significantly changed. Similarly, fluvoxamine had no effect on secretion in voltage-clamped cells stimulated with trains of brief depolarizing steps to activate I Ca (Fig. 8) . This mirrors our recent finding that escitalopram (1 lM) had no effect on KCl-evoked catecholamine secretion (Brindley et al. 2016) . Parallel effects of fluvoxamine were seen on cytosolic [Ca 2+ ]; fluvoxamine modestly (~20%) reduced the increase in cytosolic [Ca 2+ ] produced by either carbachol or DMPP ( Fig. 4e and f) but had no effect on KCl-evoked Ca 2+ entry ( Fig. 4e and f) . These data confirmed that fluvoxamine and NE-100 had no direct effects on secretion or Ca 2+ entry when the nAChRs were bypassed and suggest that sigma-1 receptors do not acutely regulate secretion. The modest reduction in cytosolic [Ca 2+ ] produced by fluvoxamine when cholinergic agonists were used likely reflects block of Ca 2+ entry directly through nAChRs. It has been shown previously that there is significant Ca 2+ entry through neuronal nAChRs in chromaffin cells (Zhou and Jones 1993; Vernino et al. 1994) . This Ca 2+ entry can trigger exocytosis even in the absence of membrane depolarization (i.e., in voltage-clamped cells) (Mollard et al. 1995; Perez-Alvarez and Albillos 2007) , and perhaps of more physiological relevance, it can augment exocytosis evoked by membrane depolarization and Ca 2+ entry via I Ca by twofold (Harkins and Fox 1998) . It is possible that other pathways are also involved such as Ca 2+ -induced Ca 2+ release from intracellular stores. Chromaffin cells also express muscarinic ACh receptors (Olivos and Artalejo 2008) , although the response to DMPP (a nicotinic agonist) and its inhibition by fluvoxamine was very similar to that seen with carbachol (Fig. 4) , suggesting that these effects are predominantly because of nicotinic signaling.
To summarize, we have previously shown that SERT expressed in chromaffin cells modulates the ability of 5-HT 1A receptors to inhibit secretion, making SERT a likely target by which SSRIs could influence chromaffin cell function. In this paper, we investigated the possibility that sigma-1 receptors might be an alternate target for SSRIs in chromaffin cells. However, our data suggest that sigma-1 receptors do not acutely regulate catecholamine secretion from chromaffin cells. The simplest explanation of our data is that block of nAChRs by fluvoxamine or NE-100 had little impact on membrane depolarization and the resultant Ca 2+ entry through I Ca , but reduced that component of Ca 2+ entry because of direct influx via the nAChRs. This reduced Ca 2+ entry through nAChRs resulted in the diminished exocytosis seen with cholinergic stimulation. It remains to be seen if sigma-1 receptor ligands can block nAChR currents in other cell types, but our data suggest that this should be considered when interpreting the actions of such drugs both in vitro and in vivo.
